A new international commission seeks to develop a framework for researchers, clinicians and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing.

The commission has been convened by the Royal Society, the U.S. National Academy of Sciences (NAS) and the U.S. National Academy of Medicine (NAM), with the participation of scientific and medical academies from around the world. The framework will identify a number of scientific, medical and ethical requirements that should be considered, and could inform the development of a potential pathway from research to clinical use.

Back to e-newsletter